-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Guolong Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Copper Chloride API
Category:
发布时间：2025-07-15
【概要描述】
On July 14, the copper chloride active pharmaceutical ingredient developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed formulations, making it the third such approval in China.
On July 14, the copper chloride active pharmaceutical ingredient developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed dosage forms, making it the third such approval in China.
According to available information, copper chloride is an inorganic salt and a raw material used in various trace-element injection solutions, primarily for supplementing the body’s need for trace elements.
The Group continues to advance its integrated “API + Formulation” development strategy. Since the beginning of this year, a total of 11 new API products have been approved, with Guolong Pharmaceutical accounting for 4 of them. To date, the Group holds 78 bulk and specialty API varieties, further strengthening its supply-chain resilience.
According to available information, copper chloride is an inorganic salt and a raw material used in various trace-element injection solutions, primarily for supplementing the body’s need for trace elements.
The Group continues to advance its integrated “API + Formulation” development strategy. Since the beginning of this year, a total of 11 new API products have been approved, with Guolong Pharmaceutical accounting for 4 of them. To date, the Group holds 78 bulk and specialty API varieties, further strengthening its supply-chain resilience.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091